Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin

Publisher： Karger

E-ISSN： 1421-9662|137|3|123-131

ISSN： 0001-5792

Source： Acta Haematologica, Vol.137, Iss.3, 2017-03, pp. : 123-131

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 35-39

Karger

Access to resources Recommend Favorite

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 74-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 1, 2015-10 ,pp. : 74-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation

By  

Acta Haematologica, Vol. 132, Iss. 2, 2014-04 ,pp. : 226-232

Karger

Access to resources Recommend Favorite